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Abstract
Currently, metabolic diseases are the main public health problem. Obesity is a 
metabolic imbalance that leads to insulin resistance, hyperinsulinemia, dyslipid-
emia, hypertension, and proinflammatory and prothrombotic states that can trigger 
type 2 diabetes as well as cardiovascular diseases. Obesity is the excess of adipose 
tissue and is considered a risk factor to develop metabolic syndrome. The obesogenic 
environment that is lived promotes the search for specific solutions that help to con-
trol, eradicate, or minimize the negative results in health, making use of the proper-
ties of flavonoids, as important sources of antioxidants, with anti-inflammatory, 
antithrombotic, and antihypertensive effects. Given the above, the objective of this 
chapter is to highlight the effects of flavonoids on the modulation of lipolysis and 
lipogenesis altered by a hyperlipidic diet.
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1. Introduction
Obesity is a major health problem worldwide. It is the result of the combination 
of genetic factors, inadequate nutrition, and lack of regular physical activity. The 
ingestion of a diet of high energy density is the main cause of visceral or central 
obesity, since the excess energy is stored in adipocytes, which increase in size and 
number, or both, especially the visceral ones, producing an increase in the rate of 
lipolysis, which, in turn, stimulates the secretion of cytokines by the infiltration 
of leukocytes, macrophages generating inflammation in the adipocytes, and leads 
to proinflammatory state, insulin resistance, and endothelial dysfunction. Thus, 
adipose tissue dysfunction represents the etiopathogenic mechanism (Figure 1) in 
the development of cardiovascular disease, type 2 diabetes, and renal disease initi-
ated by visceral obesity [1].
The WHO defines overweight and obesity as “abnormal or excessive accumula-
tion of fat that can affect health.” A person is defined as normal weight if their BMI 
is 18.5–24.9 kg/m2, overweight if the BMI is 25–29.9, or obese if the BMI is 30 or 
more [2].
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2. Mechanisms present in obesity
The number of adipocytes increases in the early age but reaches a maximum in 
youth and remains constant regardless of weight changes. In overweight or moder-
ate obesity, the cells grow by the accumulation of lipids, without increasing their 
number. However, when obesity increases to more severe levels, the number of 
adipocytes will always increase [3].
Adipose tissue can be made up of large adipocytes (hypertrophy) or many small 
ones (hyperplasia). These two mechanisms contribute to the expansion of adipose 
tissue. In adults, hypertrophy is the mechanism that predominates and has been 
detected, which is strongly related to diet, while hyperplasia depends on genetics [4].
When there is an imbalance between the amount of energy consumed and that 
used by the body, it begins to store the excess energy in the form of triglycerides 
inside the adipocytes. These adipocytes begin to become hypertrophic, which 
causes free fatty acids to be released into the circulation (lipotoxicity), as well as the 
adipocytes changing their immunological balance which promotes the production 
of proinflammatory cytokines [5].
Obesity is a chronic state of low-grade inflammation. During the develop-
ment of obesity, macrophages infiltrate the visceral white adipose tissue, causing 
chronic inflammation of low intensity that is characterized by the upregulation of 
proinflammatory adipokines such as TNFα, and decrease the concentration of anti-
inflammatory adipokines such as adiponectin. In addition, saturated fatty acids 
and TNFα, derived from adipocytes and macrophages, result in a cycle that leads to 
chronic inflammation of fat cells [6], as shown in Figure 2.
Also, during obesity, adipose tissue produces a greater amount of reactive oxygen species 
(ROS) which causes oxidative stress. This stress in turn leads to the abnormal production of 
adipokines (chronic low-grade inflammation), where it has been shown, for example, that 
the concentration of adiponectin is inversely related to the concentration of ROS [7].
2.1 Abdominal obesity
The white adipose tissue is metabolically active itself that participates in 
the metabolic regulation and physiological processes such as the inflammatory 
response, vascular function, and the secretion of hormones and adipocytokines [8].
Figure 1. 
Etiopathogenic and pathophysiological mechanisms of obesity.
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Different epidemiological studies have shown that the increase in the consump-
tion of diets high in saturated fats and simple carbohydrates leads to the progressive 
accumulation of intra-abdominal fat mass, accompanied by alterations in their 
pattern of adipocytokine secretion and in the homeostasis of the metabolism of 
lipids [9, 10].
There are two main types of adipose tissue: white adipose tissue (WAT) and 
brown adipose tissue (BAT) (Figure 3). White adipocytes are the most common fat 
cells, are present in visceral and subcutaneous adipose tissues, and are responsible 
for the expansion of fat mass in obesity. On the other hand, brown adipocytes are 
smaller cells that play a central role in the process of thermogenesis; their deposits 
are mainly focused on the interscapular and perirenal and around the great vessels, 
although their deposits are limited according to age advances [10].
In the particular case of obesity and the capacity shown by white adipocytes to 
adapt their metabolism to the energy demands of the organism, it will depend on 
the BAT to adequately perform its function as an energy reservoir (uptake of circu-
lating fatty acids, esterification, and deposition as triglycerides (TG)) and prevent 
ectopic deposits of lipids and, therefore, lipotoxicity in tissues such as the liver and 
Figure 2. 
Mechanisms of inflammation in adipose tissue. ↓Decrease, ↑increase. Interleukin 10 (IL-10), interleukin 6 
(IL-6), tumor necrosis factor alpha (TNFα), Jun kinase (JNK), necrosis factor kappa B (NF-ᴋb), free fatty 
acids (FFA).
Figure 3. 
Types of adipose tissue.
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skeletal muscle. It is important to note that in lipogenesis and TG synthesis in the 
liver due to a hypercaloric diet, the synthesized fatty acids are incorporated into the 
triacylglycerides, leading to an increase in the synthesis and secretion of very-low-
density lipoproteins (VLDL), as shown in Figure 4.
When the capacity of the WAT to store TG is exceeded, the activity of lipopro-
tein lipase of the adipocyte (LPLa) begins to decrease and with it the hydrolysis of 
TG that is transported by chylomicrons from the small intestine. In the long  
term, this generates an elevation in plasma levels of triglycerides and 
c-VLDL. Similarly, the progressive hypertrophy of adipocytes promotes tissue 
hypoxia, inflammation, and infiltration of macrophages that induce an increase in the 
secretion of various proinflammatory mediators such as tumor necrosis factor alpha 
(TNF-α), interleukin 6 (IL −6), plasminogen inhibitor 1 (PAI-1), C-reactive protein 
(CRP), and monocyte chemoattractant protein 1 (MCP-1), among others [11, 12].
The peroxisome proliferator-activated receptor gamma (PPARγ) is a transcrip-
tion factor that plays a central role in the regulation of adipogenesis (differentiation 
and proliferation of adipocytes), allowing the expansion of the TAB in response to 
a positive energy balance through the increase in the number of small adipocytes 
with high sensitivity to insulin. In addition to this, PPARγ induces the expres-
sion of genes involved in uptake (lipoprotein adipocyte lipase (LPLa)), transport 
(CD6 fatty acid transporter (FAT/CD36), fatty acid-binding protein in adipocytes 
(aFABP)), esterification, and deposition of TG (acyl-CoA synthetase (ACS), 
perilipin 1 (Plin1)) and inhibits the expression of proteins involved in lipolysis 
(hormone-sensitive lipase (HSL), monoglyceride lipase (MGL)) [13, 14]. The above 
functions prevent the secretion of free fatty acids (FFA) into portal and systemic 
circulation and, consequently, lipotoxicity and insulin resistance in peripheral tis-
sues. On the other hand, PPARγ contributes to maintain an adequate sensitivity to 
insulin through induction in the secretion of adiponectin (ApN) and leptin and the 
increase in the expression of the substrate of the insulin receptor (IRS1/2) and the 
transporter GLUT4 [15].
The oxidative function of WAT is generally underestimated. However, this 
is relevant during the process of differentiation of adipocytes in which the gene 
expression of PGC-1α is increased, a master regulator of mitochondrial biogenesis 
and oxidative metabolism [16].
The lipid droplets that are concentrated in the cytoplasm of adipocytes are 
surrounded by structural proteins and enzymes that respond to hormonal stimuli 
for lipolysis. Cyclic AMP (cAMP) is a second messenger that activates lipolysis by 
stimulating protein kinase A (PKA) which, in turn, is responsible for phosphorylat-
ing membrane protein perilipin 1 (Plin1). The latter activates the hydrolysis of the 
Figure 4. 
Lipogenesis stimulation by hypercaloric diets.
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TG stored in the lipid vacuoles through the induction of CGI-58, the coactivator of 
acyl triglyceride lipase (ATGL). Subsequently, PKA activates the hormone-sensitive 
lipase (HSL) that is responsible for hydrolyzing diacylglycerol (DAG) to mono-
acylglycerol, which will finally be hydrolyzed to obtain a non-esterified fatty acid 
(NEFA) and a glycerol molecule [10] (Figure 5)[55].
Insulin acts as a physiological inhibitor of catecholamine-induced lipolysis, since 
after stimulation of the insulin receptor (IRS-1/2) and phosphatidylinositol-3 kinase 
(PI3K), PKB is activated that phosphorylates phosphodiesterase-3B (PDE-3B) pro-
ducing the hydrolysis of cAMP. The reduction of cAMP levels and PKB activity that 
accompany the activation of PDE-3B results in net dephosphorylation and decreased 
activity of HSL, leading to decreased hydrolysis of stored TAGs [56].
The adequate regulation of the process of lipolysis will lead to the fatty acids 
released into the circulation being captured by peripheral tissues, activated (addi-
tion of an acyl-CoA group), and transported, by carnitine palmitoyl transferase-1 
(CPT-1/2), inside the mitochondrial matrix for its oxidation. However, the imbal-
ance that is generated in the metabolism of adipocytes in obesity causes a lipogenic 
state and insulin resistance that decreases the rate of oxidation and favors lipolysis. 
The latter favors the ectopic deposits of lipids in the liver, a chronic state of inflam-
mation and systemic resistance to insulin [10].
Abdominal obesity and IR in the WAT promote lipolysis and secretion of FFA into 
the portal circulation. In addition to this, an increase in plasma concentrations of 
remnant chylomicrons (rich in TG) is observed due to the absence of LPL induction 
in the liver and WAT. The hypertriglyceridemia is further accentuated by an increase 
in the synthesis and secretion of hepatic VLDLs, secondary to an increase in the por-
tal flow of FFA and an increase in the production of apolipoprotein B-100 [17]. The 
hypertriglyceridemia of MS is directly related to a reduction in the plasma concentra-
tion of HDL and an increase in small and dense LDL particles (sdLDL) [18].
Figure 5. 
Control of lipolysis in the human adipocyte. Receptors β y α2A-adrenergic (RA), Kinase A protein  
(PKA), hormone-sensitive lipase (LSH), insulin receptor (IRS-1/2), Kinase B protein (PKB), kinase  
(PI3 [PI3-k]), phosphodiesterase type 3B (PDE 3B), kinase protein (PDK1), perilipin (Plin 1),  
diglyceride (DG), monoglyceride (MG), fatty acid transporter protein (FATP), free fatty acids (FFA), acyl 
co-A synthetase (ACS), Carnitine palmitoyltransferase (CTP), reactive oxygen species (ROS). The solid arrows 
indicate the effects that appear beyond the activation of kinases. The sign indicates  stimulation and  
indicates inhibition.
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The decrease in plasma levels of HDL is the result of a decrease in the concentra-
tion of HDL3 particles (in maturation) and in a greater degree of HDL2 (mature). In 
hypertriglyceridemia, VLDL becomes prone to the reciprocal transfer of cholesterol 
esters and triglycerides with HDL2, by the action of cholesterol ester transferase 
protein (CPTE). This causes the conversion of HDL2 into smaller HDL3 particles 
rich in triglycerides that become suitable substrates for hepatic lipase (LH).
In IR, the greater induction of LH activity increases the hydrolysis of TG and 
phospholipids of HDL3 and promotes the formation of even smaller and poor HDL 
particles in cholesterol esters. They are more susceptible to renal dissociation and 
excretion of their apolipoprotein A-1 (apoA-1) [19, 20].
The decrease in plasma concentration of HDL reduces the reverse cholesterol 
transport (RCT) from the peripheral tissues to the liver for biliary excretion. As a 
result, the atherogenic processes and the elevation in total cholesterol concentra-
tions are favored [19].
At the level of the pancreatic β cell, the accumulation of intracellular cholesterol 
(due to alterations in the ABCA1 cholesterol transporter) has been shown to influ-
ence the reduction of insulin secretion and cellular degeneration that culminates in 
apoptosis [21].
IR and decreased levels of HDL are related to an increase in sdLDL levels, which 
have a great atherogenic potential that increases the risk of developing CVD. Its 
formation is the product of an increase in CPTE activity that favors the exchange 
of cholesterol esters of LDL by TG of VLDL and consequently the formation of 
TG-rich LDL particles.
Skeletal muscle is another tissue that undergoes serious metabolic alterations 
due to the elevation of plasma FFA and TG levels, since it favors the uptake and 
excessive accumulation of TGIM that diminish mitochondrial oxidation capacity 
and contribute to the development of IR in this tissue [19, 20].
It has been suggested that the increase in intramyocellular accumulation of 
lipids is mediated by an increase in the translocation of the FAT/CD36 protein 
responsible for transporting long-chain fatty acids from the extracellular space to 
the outer mitochondrial membrane, where it favors its transport by the CPT-1 for 
its subsequent oxidation. However, when the uptake of fatty acids increases, there is 
a decrease in the rate of oxidation (by increased levels of malonyl-CoA that inhibit 
CPT-1) that promotes their accumulation in the form of TG drops. This is directly 
related to the development of IR and hyperglycemic states, since the accumulation 
of fatty acid metabolites (long-chain acyl-CoA, DAG, ceramides) induces kinase 
involved in the phosphorylation of amino acid residues of the insulin receptor or of 
its substrates resulting in the interruption of the insulin signaling cascade [20, 22].
2.2 Cytokines secreted by fatty tissue
Some of the cytokines secreted by fatty tissue are listed below:
Adiponectin: It is a protein that is synthesized mainly in adipocytes [23] and 
is the cytokine most secreted by adipose tissue. Its concentration is linked to the 
ADIPOQ gene [24] and is associated with inflammation processes.
Alpha tumor necrosis factor (TNFα): It is a cytokine that is associated primar-
ily with the inflammatory response related to obesity. It also has an effect on lipid 
and glucose metabolism [25]. Studies have been conducted in humans with obesity 
showing high expression of TNFα in adipose tissue and a decreased expression of 
this factor after losing weight. It has also been shown that TNFα suppresses the 
transcription of adiponectin [26].
IL-6: It is a cytokine whose synthesis is induced by inflammatory stress and is 
involved in atherogenesis. It is believed that high levels of IL-6 are responsible for 
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the increase of proteins in obese patients, particularly CRP. This protein decreases 
the activity of lipases, which increases lipid consumption by macrophages. It has 
also been directly associated with IL-6 with the index of body mass, waist circum-
ference, and visceral fat in obese patients [27].
MCP-1: It is a chemokine that is secreted in response to the proinflammatory 
cytokines that has the function of recruiting monocytes and macrophages in case 
of inflammation or tissue damage [28]. It is involved with obesity and is secreted 
by adipose tissue. Normally the adipose tissue of slender people contains 5–10% of 
macrophages, while in obese the content of macrophages in the adipose tissue can 
reach as high as 50% of the total cells [6].
PAI-1: It is an inhibitor of serum proteases whose main function is antifibrinol-
ytic (the ability to promote the formation of clots). It has been discovered that this 
molecule is associated with the differentiation of pre-adipocytes to adipocytes, with 
the fat content in the vesicles of adipocytes and the level of leptin circulating in 
plasma [29].
Leptin: It is a hormone produced mainly by adipose tissue that is released into 
the bloodstream. Leptin levels decrease during fasting; after food intake, leptin is 
produced which sends a signal to the hypothalamus that inhibits the appetite [30]. 
However, it has been observed that in obese patients there is a phenomenon of 
resistance to leptin since in their blood high levels of this hormone have been found.
2.2.1 PPARƔ
Peroxisome proliferator-activated receptors (PPARs) are transcription factors 
belonging to a superfamily of nuclear receptors that regulate the metabolism of 
glucose and lipids.
PPARƔ is a receptor that is abundantly expressed in adipose tissue and one of the 
main regulators of glucose and insulin metabolisms. It also plays an important role 
in the transcriptional activation of adipokines, including adiponectin [31]. PPARƔ 
directly controls the expression of many genes related to the key functions of adipo-
cytes, such as lipid transport and metabolism, as well as the production of adipokines. 
It also affects the expression of genes involved with lipid metabolism such as lipid 
transport (FABP4), fatty acid absorption (LPL, FATP/SLC2/A1, OLR1), recycling of 
intracellular fatty acids (PEP-CK/PCK1, GK, AQP7), and lipolysis (GPR81) [32].
2.2.2 Oxidized low-density lipoproteins (LDLox)
The increase in vascular production of EROS not only causes a decrease in the 
synthesis and bioavailability of endothelial NO but also can react and oxidize small, 
dense low-density lipoproteins (sdLDL) that infiltrate and easily adhere to proteo-
glycans in the basal vascular lamina [33].
The presence of LDLox constitutes a crucial factor in the development of 
proinflammatory processes in the arterial vascular wall. Once these molecules 
are captured by membrane receptors of endothelial cells, they promote a series of 
proapoptotic and remodeling processes that favor the development of atherosclero-
sis and endothelial dysfunction. The increase in LDLox concentrations has also been 
associated with an increase in the proteasomal degradation of eNOS, changes in the 
ratio of eNOS: iNOS expression and with protein oxidation [34].
Similarly, LDLox are recognized and phagocytosed by macrophages that dur-
ing the process undergo changes in their conformation and become foam cells. 
These cells adhere to the smooth muscle cells of the endothelium and continue to 
accumulate lipids, which favors the formation of lipid striae that progress to form 
atheromas [35].
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It was shown that the incubation of cell cultures with (−)-epicatechin had 
a protective effect against the oxidative damage generated by the presence of 
LDLox. This reduces the activation of endothelial cells that promote inflamma-
tory responses (release of cytokines, chemokines, and angiogenic factors) and the 
production of cell adhesion molecules that facilitate the migration of macrophages 
to the vascular intima to phagocytose LDLox [36].
2.2.3 Effects of flavanols on hyperglycemia and insulin resistance
In addition to the anti-inflammatory effects that cocoa flavanols have shown, 
there are recent publications indicating that these also have beneficial effects 
on hyperglycemia and insulin resistance. These alterations are closely related to 
dyslipidemia and the presence of abdominal obesity and, consequently, to the 
pathogenesis of the metabolic syndrome [37, 38].
In a study with hypertensive patients, a vasodilator effect was observed, as well 
as a decrease in blood pressure and an improvement in blood glucose and fasting 
and postprandial insulin response, after the daily consumption of dark chocolate 
rich in flavanols [40, 41].
In another study in mice with type 2 diabetes (DT2) and obesity, it was observed 
that the administration of cocoa liquor rich in procyanidins (CLPr) decreased the 
hyperglycemia in a dose-dependent manner. The proposed mechanisms involve 
an increase in the translocation of GLUT-4 toward the cell membrane, an increase 
in phosphorylation of AMPK, and the induction of gene expression of UCP-2 in 
skeletal muscle [39, 40]. Another phenolic compound, ellagic acid, increases the 
expression of the type 4 glucose transporter (GLUT4) and the peroxisome prolifer-
ator-activated gamma receptor (PPAR-γ). Activation of the latter by pioglitazone 
upregulates adiponectin, but when combined with pure ellagic acid, this positive 
regulation is achieved at lower drug concentrations, i.e., ellagic acid is responsible 
for antidiabetic activity [41].
These results are consistent with those obtained in two studies in which it shows 
that the administration of a flavanol-rich cocoa extract in an animal model with 
DT2 has hypoglycemic and lipid-lowering effects [39, 42]. In a similar study, it was 
evaluated whether supplementation of a high-fat diet with CLPr could attenuate the 
development of obesity, insulin resistance, and hyperglycemia induced by a high-fat 
diet and that glucose levels were obtained at different doses of CLPr. Plasma fasting 
decreases, compared to the group fed with a high-fat diet without supplementation. 
Also, when performing the oral glucose tolerance test, it was observed that supple-
mentation with 2% of CLPr manages to reduce hyperglycemia and postprandial 
hyperinsulinemia [43].
Phosphatidylinositol-3-kinase (PI3K) and AMPK are the two main molecules 
involved in the regulation of GLUT4 translocation. Thus, the increase in the activa-
tion of AMPK by the administration of CLPr was related to an increase in the expres-
sion and translocation of GLUT4 and, therefore, with a higher glucose uptake.
Finally, the effect of the administration of CLPr on the protein expression of 
UCP1 (brown adipose tissue) and UCP2 (white adipose tissue and liver), involved 
in the regulation of thermogenesis and energy metabolism, was studied. The results 
showed that both concentrations of CLPr increase energy expenditure, through an 
increase in protein expression of UCP1 and UCP2 [44].
2.2.4 Effects of flavanols on alterations in lipid metabolism
Atherogenic dyslipidemia (increased levels of TG, c-LDL, and c-VLDL, accom-
panied by decreased HDL) not only constitutes one of the central criteria of the 
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metabolic syndrome but has also been shown to be directly related to the development 
of CVD. In addition to its beneficial effects on oxidation, inflammation, and endothe-
lial function, cocoa flavanols have also been shown to have lipid-lowering effects that 
attenuate the development of NCDs associated with alterations in lipid metabolism. 
There are meta-analyses of clinical trials that have shown that the consumption of 
products derived from cocoa (cocoa and dark chocolate) has beneficial effects on the 
lipid profile of patients with some type of CVD or with metabolic risk factors. Most 
studies are consistent in showing a decrease in plasma levels of CT and c-LDL; how-
ever, in relation to the increase in HDL-c levels, the results are heterogeneous [45–47].
Other studies in animals and humans (healthy or with CV risk) have also reported 
a significant decrease in plasma levels of TG, CT, and c-LDL and an increase in 
c-HDL levels, after a period of chocolate consumption dark or cocoa [48, 49].
In an animal study, the hypocholesterolemic effects of a mixture of epicatechin 
and catechin and another mixture of oligomeric procyanidins of cocoa were evalu-
ated, after the ingestion of a high cholesterol diet for 4 weeks. The results showed 
that only the procyanidin mixture significantly reduced the plasma concentrations 
of TG and increased the fecal excretion of bile salts and cholesterol, compared to the 
control group. Through an in vitro study with procyanidin B2, B5, C1, and A2, it was 
determined that a possible mechanism to explain the previous results is a decrease in 
the solubility of cholesterol in the micelles that allow intestinal absorption [50, 51].
In a recent in vitro study by Gu et al., the inhibitory effects of cocoa extracts 
and monomeric, oligomeric, and polymeric flavanols on the activity of pancreatic 
lipase and phospholipase A2 were evaluated. The results showed that the different 
extracts had inhibitory effects on the activity of both enzymes and that said effects 
are proportional to the total polyphenol content and the degree of polymerization 
of the flavanols [52].
In the liver, alterations in lipid metabolism promote an increase in its fatty infil-
tration and lipotoxicity that culminate in the development of nonalcoholic steato-
hepatitis (NASH), one of the most severe comorbidities of the metabolic syndrome 
[40, 54]. In an experimental study with rats, the preventive or palliative effects 
that cocoa supplementation could have on the development of NASH induced by 
a diet high in fat and deficient in choline were evaluated. The results showed that 
the supplementation with cocoa reduces the degree of steatosis, liver fibrosis, and 
portal inflammation. In this same study, it was observed that the supplementation 
with cocoa reduced the accumulation of fat in the liver, due to an increase in the 
levels of gene and protein expression of the fatty acid-binding protein (LFABP) in 
the hepatocytes of rats with NASH.
Another flavonoid that has positive effects in obesity is morin, suppressing 
lipogenesis, gluconeogenesis, inflammation, and oxidative stress, tending to modify 
the concentration of triacylglycerides in the liver.
A preclinical study showed that morin acts as an inhibitor of fatty acid synthase 
(FAS) by regulating the SREBP1-c protein binding element, in addition to regulat-
ing the liver increase of carnitine palmitoyl transferase 1a (CPT1a) [51, 52].
It is important to mention that morin could interact with various receptors 
involved in metabolic diseases as well as ligand of altered genes in obesity and 
therefore in the present inflammation. However, the mechanism of action of the 
flavonoid is still unknown since there are no major reports of research related to the 
mechanism and effect of it.
2.2.4.1 Effect of flavonoids of marine algae on obesity
The content of flavonoids in Undaria pinnatifida is equivalent to 42% of the 
total phenols, and several studies have shown that the main phenolic compounds 
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and flavonoids contained in this alga are rutin, caffeic acid, catechol, quercetin, and 
morin with approximately 3.1 mg/g of sample. Although there are not many reports 
regarding the content of flavonoids in Undaria, in other brown algae, the content 
varies from 0.9 to 6.3 mg/g of sample [53].
2.2.4.2 Effects of flavonoids on body fat
The content of epididymal adipose tissue (ATe), retroperitoneal (ATr), mesen-
teric (ATm), and total (%) is modified by the intake of phenols from marine algae, 
such that in the standard group with 5.10% adipose tissue, and the group that was 
given a high-fat diet, 11.33% was reached, in contrast to the group that consumed 
free phenols, the content was reduced to 8.9%.
The effect of the phenols was the reduction of the concentrations of triacylg-
lycerols in 57% with respect to the group fed with a high-fat diet; only 10% above 
the group was fed a normal diet. In relation to changes in total cholesterol levels, 
phenols decreased it by 75% with respect to the group with a high-fat diet, remain-
ing only above the group with a normal diet by 20% [58].
2.2.4.3 Clinical studies on the effect of flavonoids
Recent studies have shown the importance of the intake of flavonoids and their 
relation to the risk of chronic diseases, where the intake of flavonoids and obesity 
were inversely associated in both men and women using multivariate models in a 
study in the USA. Adults in the highest quartile of flavonoid intake had a signifi-
cantly lower body mass index and waist circumference than those in the lowest 
quartile of flavonoid intake (P < 0.03 and P < 0.04, respectively); and the ingestion 
of flavonoids was inversely related to the levels of C-reactive protein in women 
(trend p, 0.01). These findings support a growing evidence that the consumption of 
flavonoids may be beneficial for the prevention of diseases [57].
Scientific evidence has been found in clinical studies of the effect of flavonoids 
present in fruits that can be consumed regularly and be part of the diet, suggesting 
a beneficial effect for health, as is the case of anthocyanins, punicalagin, and ellagic 
acid, present in the pomegranate fruit.
The effect of flavonoids present in pomegranate juice on the function of adipo-
cytes has been studied. Using increasing doses of juice and by radiometric methods, 
the activity of the amino oxidase was determined, and with colorimetric methods 
the influence of the juice on the lipogenic and lipolytic activities of the human adi-
pose tissue was evaluated. The results showed a dose-dependent response of juice to 
inhibit the monoamine oxidase and the activity of the amino oxidases present in the 
human adipose tissue sensitive to semicarbazide. The juice also inhibits lipogenesis 
and lipolysis in human and mouse adipose cells [58].
Oral supplementation with pomegranate extract on biomarkers of inflammation 
and oxidative stress in plasma, as well as serum metabolic profiles in overweight 
and obese people, for 30 days, resulted in a significant decrease in serum glucose, 
insulin, and blood levels, total cholesterol, concentration of low density lipopro-
teins LDL-c, MDA and IL-6. It is concluded that the consumption of pomegranate 
extract can reduce complications related to obesity [59].
The functionality of flavonoids in various diseases has been demonstrated, and 
these have been part of our diet all the time, since they are found abundantly in fruits, 
vegetables, and grains that we consume, such as apples, grapes, blueberries, pome-
granates, oranges, broccoli, spinach, thyme, cocoa, nuts, and soybeans, to name a few.
However, the concern that the benefits of these compounds have aroused in 
the food industry is wide, since, from these natural sources, products containing 
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flavonoids are manufactured, enriching, fortifying, or increasing the concentration 
of flavonoids present in various products to have a positive effect on health. In the 
market there are various products rich in flavonoids such as fruit and vegetable 
juices, wines, cereals, milk formulas, soy milk, almond milk, confectionery, rice 
drinks, relaxing drinks, food supplements, and capsules containing extracts of 
flavonoids. The development of new functional products is increased due to the 
need to contribute to the health welfare.
3. Conclusions
Although there is sufficient evidence on the beneficial effect of flavonoids in 
relation to the improvement in health status in metabolic diseases such as obesity, 
where flavonoids contribute to recover the lost balance due to the deregulation of 
lipogenesis and lipolysis, much remains to be done to clarify aspects such as the 
adequate concentrations suitable for use in drug design, the interactions between 
the different compounds present, as well as the modifications in the absorption of 
them depending on the changes in the health states. It is also necessary to deepen 
into the reaction mechanisms involved for a better management of these com-
pounds according to each pathology.
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